Compare AbbVie Inc (ABBV) vs iShares Russell 2000 ETF (IWM) Price & Performance

AbbVie (ABBV) trades at $252.61, down 0.84% on the day, with a bullish technical outlook supported by moving averages and strong support at $248. The company reported revenue of $61.16B in 2025, with EPS beats in recent quarters, though net income margin has trended down to 5.79%. Key growth drivers Skyrizi and Rinvoq are offsetting Humira declines, with positive clinical updates like the Phase 2 ELAHERE data at SGO 2026.

The stock offers a compelling buy case with a consensus price target of $266.33 (5.4% upside) and strong analyst support (68% buy ratings). However, risks include patent cliffs in the 2030s, high debt levels, and margin pressure. Dividend growth is recovering, supporting income investors, but execution on pipeline assets remains critical for sustained expansion.

IWM (iShares Russell 2000 ETF) trades at $298.90, up 0.46% with a bullish technical signal supported by moving averages. The ETF holds nearly 2,000 small-cap stocks and has gained 22.1% year-to-date, outperforming major indices. Recent news highlights small-cap strength amid shifting rate expectations, though key financial ratios remain undisclosed in current data.

Outlook remains positive given small-cap momentum and potential rate cuts, but risks include higher volatility and economic sensitivity. The ETF's diversification offers growth exposure, yet investors should weigh valuation concerns and market concentration against historical underperformance versus broad market indices over longer periods.